responding < response < responses

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references

Number of relevant bibliographic references: 68.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000011 (2020)	Binqing Fu ; Xiaoling Xu ; Haiming Wei	Why tocilizumab could be an effective treatment for severe COVID-19?
000014 (2020)	Puja Mehta ; Jessica J. Manson	What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?
000035 (2020)	Limin Li [République populaire de Chine] ; Jie Liu [République populaire de Chine] ; Mengyuan Xu [République populaire de Chine] ; Hongjuan Yu [République populaire de Chine] ; Chengfang Lv [République populaire de Chine] ; Fenglin Cao [République populaire de Chine] ; Zhenkun Wang [République populaire de Chine] ; Yueyue Fu [République populaire de Chine] ; Mingwen Zhang [République populaire de Chine] ; Hongbin Meng [République populaire de Chine] ; Xiaoqian Zhang [République populaire de Chine] ; Liqing Kang [République populaire de Chine] ; Zhuo Zhang [République populaire de Chine] ; Jinmei Li [République populaire de Chine] ; Jiawei Feng [République populaire de Chine] ; Xin Lian [République populaire de Chine] ; Lei Yu [République populaire de Chine] ; Jin Zhou [République populaire de Chine]	Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients
000055 (2020)	Pan Luo [République populaire de Chine] ; Yi Liu [République populaire de Chine] ; Lin Qiu [République populaire de Chine] ; Xiulan Liu [République populaire de Chine] ; Dong Liu [République populaire de Chine] ; Juan Li [République populaire de Chine]	Tocilizumab treatment in COVID-19: A single center experience.
000076 (2020)	Philip George [Nouvelle-Zélande] ; Nathaniel Dasyam [Nouvelle-Zélande] ; Giulia Giunti [Nouvelle-Zélande] ; Brigitta Mester [Nouvelle-Zélande] ; Evelyn Bauer [Nouvelle-Zélande] ; Bethany Andrews [Nouvelle-Zélande] ; Travis Perera [Nouvelle-Zélande] ; Tess Ostapowicz [Nouvelle-Zélande] ; Chris Frampton [Nouvelle-Zélande] ; Peng Li [République populaire de Chine] ; David Ritchie [Australie] ; Catherine M. Bollard [États-Unis] ; Ian F. Hermans [Nouvelle-Zélande] ; Robert Weinkove [Nouvelle-Zélande]	Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)
000081 (2020)	Francisco Vílchez-Oya [Espagne] ; Julia María Sánchez-Schmidt [Espagne] ; Anna Agustí [Espagne] ; Ana Pros [Espagne]	The use of tocilizumab in the treatment of refractory eosinophilic fasciitis: a case-based review.
000087 (2020)	Wanhai Ke ; Li Zhang ; Yan Dai	The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
000102 (2020)	Xiaoyan He [République populaire de Chine] ; Qingyan Ma [République populaire de Chine] ; Yajuan Fan [République populaire de Chine] ; Binbin Zhao [République populaire de Chine] ; Wei Wang [République populaire de Chine] ; Feng Zhu [République populaire de Chine] ; Xiancang Ma [République populaire de Chine] ; Lina Zhou [République populaire de Chine]	The Role of Cytokines in Predicting the Efficacy of Acute Stage Treatment in Patients with Schizophrenia
000109 (2020)	Eric Toussirot [France]	The Interrelations between Biological and Targeted Synthetic Agents Used in Inflammatory Joint Diseases, and Obesity or Body Composition
000114 (2020)	Pia M. Vidal [Chili] ; Rodrigo Pacheco [Chili]	The Cross-Talk Between the Dopaminergic and the Immune System Involved in Schizophrenia
000119 (2020)	Ana Paula Vargas Visentin [Brésil] ; Rafael Colombo [Brésil] ; Ellen Scotton [Brésil] ; Débora Soligo Fracasso [Brésil] ; Adriane Ribeiro Da Rosa [Brésil] ; Catia Santos Branco [Brésil] ; Mirian Salvador [Brésil]	Targeting Inflammatory-Mitochondrial Response in Major Depression: Current Evidence and Further Challenges
000134 (2020)	Ayush Gupta [Inde] ; Narendra Kumar Bagri [Inde] ; Saroj Kumar Tripathy [Inde] ; Adarsh Barwad [Inde] ; Ravi Hari Phulware [Inde] ; Pankaj Hari [Inde]	Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis.
000143 (2020)	Eduardo Mysler [Argentine] ; Mario H. Cardiel [Mexique] ; Ricardo M. Xavier [Brésil] ; Alejandra L Pez ; Allan Ramos-Esquivel [Costa Rica]	Subcutaneous Tocilizumab in Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Latin American Patients With Moderate to Severe Active Rheumatoid Arthritis: A Multicenter, Phase IIIb Study.
000159 (2020)	Cem Gabay [Suisse] ; Gerd R. Burmester [Allemagne] ; Vibeke Strand [États-Unis] ; Jérôme Msihid [France] ; Moshe Zilberstein [États-Unis] ; Toshio Kimura [États-Unis] ; Hubert Van Hoogstraten [États-Unis] ; Susan H. Boklage [États-Unis] ; Jonathan Sadeh [États-Unis] ; Neil M. H. Graham [États-Unis] ; Anita Boyapati [États-Unis]	Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
000166 (2020)	Elyes Bouajina [Tunisie] ; Leith Zakraoui [Tunisie] ; Montassar Kchir [Tunisie] ; Samir Kochbati [Tunisie] ; Sofiene Baklouti [Tunisie]	Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice.
000172 (2020)	Di Mauro Gabriella ; Scavone Cristina ; Rafaniello Concetta ; Rossi Francesco ; Capuano Annalisa	SARS-Cov-2 infection: response of human immune system and possible implications for the rapid test and treatment
000178 (2020)	Adelaide Sofia Batalha Figueiredo [Portugal] ; Ana Luísa Oliveira [Portugal] ; Ant Nio Caetano [Portugal] ; Maria Francisca Moraes-Fontes [Portugal]	SAPHO: has the time come for tailored therapy?
000180 (2020)	Emily Yi-Chih Ting ; Albert C. Yang [États-Unis] ; Shih-Jen Tsai [Taïwan]	Role of Interleukin-6 in Depressive Disorder
000190 (2020)	Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Kei Ikeda [Japon] ; Tomonori Ishii [Japon] ; Kosaku Murakami [Japon] ; Hyota Takamatsu [Japon] ; Yoshiya Tanaka [Japon] ; Takayuki Abe [Japon] ; Tsutomu Takeuchi [Japon]	Response to: 'Some concerns from Turkey' by Bilgin et al.
000191 (2020)	Yoshiya Tanaka [Japon] ; Hideto Kameda [Japon] ; Kazuyoshi Saito [Japon] ; Yuko Kaneko [Japon] ; Eiichi Tanaka [Japon] ; Shinsuke Yasuda [Japon] ; Naoto Tamura [Japon] ; Keishi Fujio [Japon] ; Takao Fujii [Japon] ; Toshihisa Kojima [Japon] ; Tatsuhiko Anzai [Japon] ; Chikuma Hamada [Japon] ; Yoshihisa Fujino [Japon] ; Shinya Matsuda [Japon] ; Hitoshi Kohsaka [Japon]	Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study.
000197 (2020)	Angela Ceribelli [Italie] ; Francesca Motta [Italie] ; Maria De Santis [Italie] ; Aftab A. Ansari [États-Unis] ; William M. Ridgway [États-Unis] ; M. Eric Gershwin [États-Unis] ; Carlo Selmi [Italie]	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "response" 

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "response" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    response
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021